🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/05/2011 | 53,51 | 56,10 | 53,30 | 55,31 | +1,04% | 5,23% | 2.620.100 |
| 03/05/2011 | 55,00 | 55,27 | 53,97 | 54,74 | -0,56% | 2,36% | 1.900.000 |
| 02/05/2011 | 55,00 | 56,70 | 54,87 | 55,05 | +0,00% | 3,33% | 2.665.900 |
| 29/04/2011 | 55,99 | 56,21 | 54,50 | 55,05 | -0,88% | 3,05% | 5.887.600 |
| 28/04/2011 | 55,54 | 55,54 | 55,54 | 55,54 | +0,00% | 0,00% | 0 |
| 27/04/2011 | 52,83 | 55,79 | 52,75 | 55,54 | +4,95% | 5,75% | 4.869.200 |
| 26/04/2011 | 48,93 | 54,99 | 47,18 | 52,92 | +10,16% | 15,96% | 12.300.000 |
| 25/04/2011 | 50,00 | 50,48 | 47,52 | 48,04 | -2,69% | 5,92% | 2.842.700 |
| 21/04/2011 | 47,84 | 49,87 | 47,84 | 49,37 | +2,90% | 4,24% | 2.889.400 |
| 20/04/2011 | 47,36 | 48,45 | 47,36 | 47,98 | +2,48% | 2,30% | 1.501.000 |
| 19/04/2011 | 47,00 | 47,15 | 46,38 | 46,82 | -0,36% | 1,64% | 1.668.500 |
| 18/04/2011 | 47,56 | 47,66 | 46,15 | 46,99 | -2,14% | 3,17% | 1.629.100 |
| 15/04/2011 | 47,75 | 48,11 | 46,79 | 48,02 | +0,90% | 2,76% | 2.062.200 |
| 14/04/2011 | 47,00 | 47,90 | 46,69 | 47,59 | +0,40% | 2,57% | 1.953.800 |
| 13/04/2011 | 48,15 | 48,34 | 46,82 | 47,40 | -1,19% | 3,16% | 1.932.300 |
| 12/04/2011 | 47,85 | 48,20 | 47,44 | 47,97 | -0,52% | 1,59% | 1.283.400 |
| 11/04/2011 | 48,28 | 48,94 | 47,57 | 48,22 | +0,12% | 2,84% | 2.147.000 |
| 08/04/2011 | 47,00 | 48,20 | 46,88 | 48,16 | +2,66% | 2,81% | 1.853.800 |
| 07/04/2011 | 46,50 | 47,25 | 46,15 | 46,91 | +1,06% | 2,37% | 1.523.900 |
| 06/04/2011 | 47,28 | 47,37 | 46,16 | 46,42 | -0,68% | 2,56% | 2.321.100 |
| 05/04/2011 | 47,32 | 47,60 | 46,52 | 46,74 | -1,58% | 2,28% | 2.760.700 |
| 04/04/2011 | 47,91 | 48,11 | 47,22 | 47,49 | -0,21% | 1,86% | 2.556.800 |
| 01/04/2011 | 48,00 | 48,20 | 47,21 | 47,59 | -0,71% | 2,06% | 2.610.200 |
| 31/03/2011 | 48,44 | 48,83 | 47,25 | 47,93 | -1,13% | 3,26% | 2.659.200 |
| 30/03/2011 | 49,30 | 49,81 | 48,39 | 48,48 | -0,86% | 2,88% | 1.881.200 |
| 29/03/2011 | 48,40 | 49,22 | 47,82 | 48,90 | +3,30% | 2,89% | 3.629.000 |
| 28/03/2011 | 46,83 | 47,60 | 46,32 | 47,34 | +1,63% | 2,73% | 1.862.700 |
| 25/03/2011 | 47,00 | 47,25 | 46,35 | 46,58 | -0,70% | 1,91% | 1.525.500 |
| 24/03/2011 | 46,20 | 47,22 | 45,83 | 46,91 | +1,80% | 3,01% | 1.676.000 |
| 23/03/2011 | 45,92 | 46,31 | 45,41 | 46,08 | -0,17% | 1,96% | 1.910.000 |